

31 May 2016

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2014/15 Invitation to Tender, dated 6 November 2014, and the 2015/16 Invitation to Tender, dated 6 November 2015.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical name | Presentation; Pack size and type | Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---------------|---|-----------------------------------|----------------------------------|---------------------------------|--|--|---|---|
| Tobramycin | Inj 40 mg per ml, 2 ml vial, 5 vials | \$38.00 | \$15.00 | Tobramycin Mylan (Mylan) | 1 December 2016 | 1 February 2017 | 1 May 2017 | DBL Tobramycin (Hospira) |

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current price | New price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---------------|--|------------------|-----------|-------------------------------------|-------------|-----------------|--------------------------------|--|
| Midazolam | Inj 1 mg per ml, 5 ml ampoule, 10 ampoules | \$10.75 | \$4.30 | Midazolam-Claris (AFT) | 5% | 1 October 2016 | 1 December 2016 | Hypnovel (Roche) Pfizer (Pfizer) |
| Midazolam | Inj 5 mg per ml, 3 ml ampoule, 5 ampoules | \$11.90 | \$2.50 | Midazolam-Claris (AFT) | 5% | 1 October 2016 | 1 December 2016 | Hypnovel (Roche) Pfizer (Pfizer) |
| Tobramycin | Inj 40 mg per ml, 2 ml vial, 5 vials | \$38.00 | \$15.00 | Tobramycin Mylan (Mylan) | 1% | 1 December 2016 | 1 February 2017 | DBL Tobramycin (Hospira) |

2015/16 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2019

CORRECTION to May 2016 tender notification: in bold and strikethrough

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

| Chemical name | Presentation; Pack size and type | Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|-----------------------------|--|-----------------------------------|-------------------------------|---------------------------------------|------------------------|--------------------------------|
| Amisulpride* | Oral liq 100 mg per ml, 60 ml | \$52.50 | \$65.53 | Solian (Sanofi) | 1 August 2016 | 1 November 2016 |
| Clotrimazole | Vaginal crm 1% with applicators, 35 g OP | \$1.45 | \$1.60 | Clomazol (Multichem) | 1 September 2016 | 1 December 2016 |
| Clotrimazole | Vaginal crm 1 2 % with applicators, 20 g OP | \$2.20 | \$2.10 | Clomazol (Multichem) | 1 September 2016 | 1 December 2016 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 1 ml ampoule, 20 ampoules | \$3.26 | \$3.35 | Univent (Rex Medical) | 1 October 2016 | 1 January 2017 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 2 ml ampoule, 20 ampoules | \$3.37 | \$3.52 | Univent (Rex Medical) | 1 October 2016 | 1 January 2017 |
| Omeprazole | Inj 40 mg ampoule with diluent, 5 ampoules | \$33.65 | \$33.98 | Dr Reddy's Omeprazole (Dr Reddy's) | 1 July 2016 | 1 October 2016 |
| Oxybutynin | Oral liq 5 mg per 5 ml, 473 ml | \$56.45 | \$60.40 | Apo-Oxybutynin (Apotex) | 1 July 2016 | 1 October 2016 |
| Oxybutynin | Tab 5 mg, 500 tablets | \$11.20 | \$8.85 | Apo-Oxybutynin (Apotex) | 1 July 2016 | 1 October 2016 |
| Ropinirole hydrochloride | Tab 0.25 mg, 100 tablets | \$2.36 | \$2.78 | Apo-Ropinirole (Apotex) | 1 July 2016 | 1 October 2016 |
| Ropinirole hydrochloride | Tab 1 mg, 100 tablets | \$5.32 | \$5.00 | Apo-Ropinirole (Apotex) | 1 July 2016 | 1 October 2016 |
| Ropinirole | Tab 2 mg, 100 tablets | \$7.72 | \$7.72 | Apo-Ropinirole | 1 July 2016 | 1 October 2016 |

| Chemical name | Presentation; Pack size and type | Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|--|-------------------------------------|-----------------------------------|-------------------------------|---------------------------------|------------------------|--------------------------------|
| hydrochloride | | | | (Apotex) | | |
| Ropinirole hydrochloride | Tab 5 mg, 100 tablets | \$14.48 | \$16.51 | Apo-Ropinirole (Apotex) | 1 July 2016 | 1 October 2016 |
| Sodium chloride | Inj 0.9%, bag, 500 ml | \$3.06 | \$1.23 | Baxter (Baxter) | 1 July 2016 | 1 October 2016 |
| Sodium chloride | Inj 0.9%, bag, 1,000 ml | \$4.06 | \$1.26 | Baxter (Baxter) | 1 July 2016 | 1 October 2016 |
| Terazosin | Tab 1 mg, 28 tablets | \$0.50 | \$0.59 | Actavis (Actavis) | 1 July 2016 | 1 October 2016 |
| <p>*Amisulpride will be supplied by Sanofi at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2015/16 Invitation To Tender.</p> | | | | | | |

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical name | Presentation; Pack size and type | Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|-------------------------|-------------------------------------|-----------------------------------|-------------------------------|---------------------------------|--|--|---|---|
| Ceftriaxone | Inj 500 mg vial, 1 vial | \$1.50 | \$1.20 | DEVA (Deva Holdings) | 1 September 2016 | 1 November 2016 | 1 February 2017 | Ceftriaxone-AFT (AFT) |
| Ceftriaxone | Inj 1 g vial. 1 vial | \$5.22 per 5 vials | \$0.84 per vial | DEVA (Deva Holdings) | 1 September 2016 | 1 November 2016 | 1 February 2017 | Ceftriaxone-AFT (AFT) |
| Paroxetine ¹ | Tab 20 mg, 90 tablets | \$4.32 | \$4.02 | Apo-Paroxetine (Apotex) | 1 February 2017 | 1 April 2017 | 1 July 2017 | Loxamine (Mylan) |
| Terazosin | Tab 2 mg, 500 tablets | \$0.45 per 28 tablets | \$7.50 per 500 tablets | Apo-Terazosin (Apotex) | 1 December 2016 | 1 February 2017 | 1 May 2017 | Arrow (Actavis) |

| Chemical name | Presentation; Pack size and type | Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|--|-------------------------------------|--|----------------------------------|---------------------------------|--|--|---|---|
| Terazosin | Tab 5 mg, 500 tablets | \$0.57 \$0.68 per 28 tablets | \$10.90 per 500 tablets | Apo-Terazosin (Apotex) | 1 December 2016 | 1 February 2017 | 1 May 2017 | Arrow (Actavis) |
| ¹ Brand switch fee of \$4.33 is payable for this product from 1 July 2017 until 1 October 2017. | | | | | | | | |

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

CORRECTION to May 2016 tender notification: in bold and strikethrough

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current price | New price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|--------------------------|--|--------------------------------------|-----------|------------------------------------|----------|------------------|-----------------------------|
| Amisulpride* | Oral liq 100 mg per ml, 60 ml | \$52.50 | \$65.53 | Solian (Sanofi) | 1% | 1 August 2016 | 1 October 2016 |
| Clotrimazole | Vaginal crm 1% with applicators, 35 g OP | \$1.45 | \$1.60 | Clomazol (Multichem) | 1% | 1 September 2016 | 1 November 2016 |
| Clotrimazole | Vaginal crm 1 2% with applicators, 20 g OP | \$2.20 | \$2.10 | Clomazol (Multichem) | 1% | 1 September 2016 | 1 November 2016 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 1 ml ampoule, 20 ampoules | \$3.26 | \$3.35 | Univent (Rex Medical) | 1% | 1 October 2016 | 1 December 2016 |
| Ipratropium bromide | Nebuliser soln, 250 mcg per ml, 2 ml ampoule, 20 ampoules | \$3.37 | \$3.52 | Univent (Rex Medical) | 1% | 1 October 2016 | 1 December 2016 |
| Omeprazole | Inj 40 mg ampoule with diluent, 5 ampoules | \$28.65 \$33.65 | \$33.98 | Dr Reddy's Omeprazole (Dr Reddy's) | 1% | 1 July 2016 | 1 September 2016 |
| Oxybutynin | Oral liq 5 mg per 5 ml, 473 ml | \$56.45 | \$60.40 | Apo-Oxybutynin (Apotex) | 1% | 1 July 2016 | 1 September 2016 |
| Oxybutynin | Tab 5 mg, 500 tablets | \$11.20 | \$8.85 | Apo-Oxybutynin (Apotex) | 1% | 1 July 2016 | 1 September 2016 |
| Ropinirole hydrochloride | Tab 0.25 mg, 100 tablets | \$2.36 | \$2.78 | Apo-Ropinirole (Apotex) | 1% | 1 July 2016 | 1 September 2016 |
| Ropinirole hydrochloride | Tab 1 mg, 100 tablets | \$5.32 | \$5.00 | Apo-Ropinirole (Apotex) | 1% | 1 July 2016 | 1 September 2016 |
| Ropinirole hydrochloride | Tab 2 mg, 100 tablets | \$7.72 | \$7.72 | Apo-Ropinirole (Apotex) | 1% | 1 July 2016 | 1 September 2016 |
| Ropinirole hydrochloride | Tab 5 mg, 100 tablets | \$14.48 | \$16.51 | Apo-Ropinirole (Apotex) | 1% | 1 July 2016 | 1 September 2016 |

| Chemical Name | Presentation; Pack size and type | Current price | New price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|--|---|----------------|----------------------|----------------------------------|----------|--------------|-----------------------------|
| Sodium chloride | Inj 0.45%, bag, 500 ml, 18 bags | \$5.50 per bag | \$71.28 per 18 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium chloride | Inj 0.9%, bag, 50 ml, 60 bags | \$3.01 per bag | \$109.80 per 60 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium chloride | Inj 0.9%, bag, 100 ml, 48 bags | \$2.28 per bag | \$78.24 per 48 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium chloride | Inj 0.9%, bag, 250 ml, 24 bags | \$3.60 per bag | \$44.64 per 24 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium chloride | Inj 3%, bag, 1,000 ml, 12 bags | \$5.69 per bag | \$91.20 per 12 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium hyaluronate [hyaluronic acid] | Inj 14 mg per ml, 0.55 ml syringe, 1 syringe | \$50.00 | \$50.00 | Healon GV (Abbott) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium hyaluronate [hyaluronic acid] | Inj 14 mg per ml, 0.85 ml syringe; 1 syringe | \$50.00 | \$50.00 | Healon GV (Abbott) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate | Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe, 1 treatment pack | \$74.00 | \$74.00 | DuoVisc (Alcon) | 1% | 1 July 2016 | 1 September 2016 |
| Terazosin | Tab 1 mg, 28 tablets | \$0.50 | \$0.59 | Actavis (Actavis) | 1% | 1 July 2016 | 1 September 2016 |
| Water for injection | Inj, bag, 1,000 ml, 12 bags | \$2.75 per bag | \$19.08 per 12 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 |
| *Amisulpride will be supplied by Sanofi at the Price from the 1 st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2015/16 Invitation To Tender. | | | | | | | |

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

| Chemical Name | Presentation; Pack size and type | Current price | New price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|-----------------|---|---|-------------------------------|--------------------------------------|----------|------------------|-----------------------------|--|
| Ceftriaxone | Inj 500 mg vial, 1 vial | \$1.50 | \$1.20 | DEVA (Deva Holdings) | 1% | 1 September 2016 | 1 November 2016 | Ceftriaxone-AFT (AFT) |
| Ceftriaxone | Inj 1 g vial, 1 vial | \$5.22 per 5 vials | \$0.84 per vial | DEVA (Deva Holdings) | 1% | 1 September 2016 | 1 November 2016 | Ceftriaxone-AFT (AFT) |
| Iloprost | Inj 50 mcg in 0.5 ml ampoule, 5 ampoules | \$89.50 per ampoule | \$380.00 per 5 ampoules | Ilomedin (Bayer) | 1% | 1 November 2016 | 1 January 2017 | Arrow – Iloprost (Actavis) |
| Omeprazole | Inj 40 mg vial, 5 vial | \$19.00 | \$13.00 | Omezol IV (Mylan) | 1% | 1 November 2016 | 1 January 2017 | Dr Reddy's Omeprazole (Dr Reddy's) |
| Ondansetron | Inj 2 mg per ml, 2 ml ampoule, 5 ampoules | \$1.82 | \$1.50 | Ondansetron-Clarix (AFT) | 1% | 1 July 2016 | 1 September 2016 | Ondanaccord (Actavis) |
| Ondansetron | Inj 2 mg per ml, 4 ml ampoule, 5 ampoules | \$2.18 | \$2.20 | Ondansetron Kabi (Fresenius Kabi) | 1% | 1 July 2016 | 1 September 2016 | Ondanaccord (Actavis) |
| Paroxetine | Tab 20 mg, 90 tablets | \$4.32 | \$4.02 | Apo-Paroxetine (Apotex) | 1% | 1 February 2017 | 1 April 2017 | Loxamine (Mylan) |
| Sodium chloride | Inj 0.9%, bag, 500 ml, 18 bags | \$1.77 per bag (Baxter) \$1.70 per bag (Fresenius Kabi) | \$22.14 per 18 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 | Freeflex (Fresenius Kabi) |
| Sodium chloride | Inj 0.9%, bag, 1,000 ml, 12 bags | \$1.80 per bag | \$15.12 per 12 bags | Baxter (Baxter) | 1% | 1 July 2016 | 1 September 2016 | Freeflex (Fresenius Kabi) |

| Chemical Name | Presentation; Pack size and type | Current price | New price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|--|--|-------------------------------|-------------------------------------|-------------|-----------------|--------------------------------|--|
| | | (Baxter) \$1.71 per bag (Fresenius Kabi) | | | | | | |
| Sodium hyaluronate [hyaluronic acid] | Inj 10 mg per ml, 0.85 ml syringe, 1 syringe | \$30.00 | \$28.50 | Healon (Abbott) | 1% | 1 July 2016 | 1 September 2016 | Provisc (Alcon) |
| Terazosin | Tab 2 mg, 500 tablets | \$0.45 per 28 tablets | \$7.50 per 500 tablets | Apo-Terazosin (Apotex) | 1% | 1 December 2016 | 1 February 2017 | Arrow (Actavis) |
| Terazosin | Tab 5 mg, 500 tablets | \$0.68 per 28 tablets | \$10.90 per 500 tablets | Apo-Terazosin (Apotex) | 1% | 1 December 2016 | 1 February 2017 | Arrow (Actavis) |

7. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

| Chemical name | Presentation; Pack size and type | Pack Price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|--|--|------------|-------------------------------------|-------------|--------------|--------------------------------|
| Sodium hyaluronate [hyaluronic acid] | Inj 23 mg per ml, 0.60 ml syringe, 1 syringe | \$60.00 | Healon 5 (Abbott) | 1% | 1 July 2016 | 1 September 2016 |
| Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate | Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe, 1 syringe | \$67.00 | Viscoat (Alcon) | 1% | 1 July 2016 | 1 September 2016 |

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2015/16 Invitation to Tender, dated 6 November 2015:

2015/16 Invitation to Tender

| Chemical Name | Line Item | Chemical Name | Line Item |
|--|---|--|---|
| Acetazolamide | Inj 500 mg | Ibuprofen | Inj 5 mg per ml, 2 ml |
| Acetic acid with propylene glycol | Ear drops 2.3% with propylene glycol 2.8% | Ibuprofen | Inj 10 mg per ml, 2 ml |
| Acetylcholine chloride | Inj 20 mg vial with diluent | Isosorbide mononitrate | Tab long-acting 60 mg |
| Albendazole | Tab 200 mg | Lidocaine [lignocaine] hydrochloride with adrenaline | Inj 1% with adrenaline 1:100,000, 5 ml |
| Albendazole | Tab 400 mg | Lidocaine [lignocaine] hydrochloride with adrenaline | Inj 1% with adrenaline 1:200,000, 20 ml |
| Alteplase | Inj 10 mg | Lidocaine [lignocaine] hydrochloride with adrenaline | Inj 2% with adrenaline 1:200,000, 20 ml |
| Alteplase | Inj 50 mg | Liposomal daunorubicin | Inj 50 mg |
| Alteplase | Inj 2 mg | Metoclopramide hydrochloride | Oral liq 5 mg per 5 ml |
| Artemether with lumefantrine | Tab 20 mg with lumefantrine 120 mg | Mexiletine | Cap 150 mg |
| Artesunate | Inj 60 mg | Mexiletine | Cap 250 mg |
| Aspirin | Suppos 300 mg | Nitazoxanide | Oral 100 mg per 5 ml |
| Betamethasone valerate with clioquinol | Crn 0.1% with clioquinol 3% | Nitrofurantoin | Oral liq |
| Betamethasone valerate with | Oint 0.1% with clioquinol 3% | Nitrofurantoin | Tab modified-release 50 mg |

| Chemical Name | Line Item | Chemical Name | Line Item |
|-----------------------------------|-----------------------------|--|---|
| clioquinol | | | |
| Bupropion hydrochloride | Tab modified-release 150 mg | Pancuronium bromide | Inj 2 mg per ml, 2 ml |
| Ceftriaxone | Inj 2 g | Pentoxifylline [oxpentifylline] | Tab 400 mg |
| Chloroquine phosphate | Tab 250 mg | Praziquantel | Tab 600 mg |
| Chlortalidone [chlorthalidone] | Tab 25 mg | Prednisolone acetate | Eye drops 0.12% |
| Cholestyramine | Powder for oral liq 4 g | Primaquine phosphate | Tab 7.5 - 15 mg |
| Ciprofloxacin | Eye Drops 0.3% | Propranolol | Oral liq 4 mg per ml |
| Ciprofloxacin | Ear drops 0.3% | Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate | Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe |
| Clofazimine | Cap 50 mg | Sodium nitroprusside | Inj 50 mg |
| Clomiphene citrate | Tab 50 mg | Sulphadiazine | Tab 500 mg |
| Cyclizine lactate | Inj 50 mg per ml, 1 ml | Trimethoprim with sulphamethoxazole [Co- trimoxazole] | Tab trimethoprim 80 mg and sulphamethoxazole 400 mg |
| Cyclophosphamide | Tab 50 mg | Trimethoprim with sulphamethoxazole [Co- trimoxazole] | Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml |
| Cycloserine | Cap 250 mg | Vecuronium | Inj 10 mg |
| Cytarabine | Inj 100 mg | Vecuronium | Inj 4 mg |
| Flucytosine | Cap 500 mg | Water for injection | Purified for injection, 500 ml bag |
| Framycetin sulphate | Ear/Eye drops 0.5% | | |
| Haloperidol decanoate | Inj 100 mg per ml, 1 ml | | |
| Haloperidol decanoate | Inj 50 mg per ml, 1 ml | | |

| Chemical Name | Line Item | Chemical Name | Line Item |
|------------------------|--------------------------|---------------|-----------|
| Hyoscine (Scopolamine) | Patches, 1.5 mg | | |
| Hyoscine hydrobromide | Inj 400 mcg per ml, 1 ml | | |
| Hypromellose | Eye drops 0.5% | | |

For products included in the 2014/15 and 2015/16 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.